Pulminiq Benefit Could Be Confirmed With Placebo Trial, Cmte. Members Say
Chiron should confirm a potential survival benefit seen with Pulminiq in a Phase II trial of lung transplant patients with a randomized, placebo-controlled trial, members of FDA's Pulmonary-Allergy Drugs Advisory Committee said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011